AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19268889 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaVision intracorneal lens implantation
Number of subjects: 15
Study 16769932 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS and placebo medication
Number of subjects: 26
Study 16769932 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 26
Study 12776447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler (400 micrograms) once daily
Number of subjects: 177
Study 12776447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 10669275 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 60 mg kg(‐1) i.v.
Number of subjects: 10
Study 10669275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg kg(‐1) i.v.
Number of subjects: 10
Study 10669275 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 9062568 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy combined with incentive spirometry (IS)
Number of subjects: 185
Study 9062568 — intervention group
Group type: COMPARATOR
Intervention: Postoperative pulmonary physical therapy (breathing exercises, secretion removal, mobility)
Number of subjects: 185
Study 8406337 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (HGH) 4 IU/m2/day for 2 years
Number of subjects: 72
Study 8406337 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (HGH) 3 IU/m2/day for 2 years
Number of subjects: 72
Study 8406337 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (HGH) 2 IU/m2/day for 2 years
Number of subjects: 72
Study 8406337 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 2871239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal phonogram measurement
Number of subjects: 12
Study 2871239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal phonogram measurement during fetal breathing
Number of subjects: 12
Study 29579957 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1 - received general information and information about the benefits (positive attributes)
Number of subjects: 432
Study 29579957 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 2 - received general information and information about the potential drawbacks (negative attributes)
Number of subjects: 432
Study 29579957 — intervention group
Group type: COMPARATOR
Intervention: Control group - received only general information
Number of subjects: 432
Study 27094628 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (T)
Number of subjects: 0
Study 27094628 — intervention group
Group type: COMPARATOR
Intervention: Diet-induced weight loss (D)
Number of subjects: 0
Study 27094628 — intervention group
Group type: COMPARATOR
Intervention: Exercise without weight loss (T-iD)
Number of subjects: 0
Study 23680682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization within 24 hours of hospitalization
Number of subjects: 52
Study 23680682 — intervention group
Group type: COMPARATOR
Intervention: Mobilization between 24 to 48 hours after hospitalization
Number of subjects: 52
Study 22723581 — intervention group
Group type: EXPERIMENTAL
Intervention: high-MUFA diet
Number of subjects: 45
Study 22723581 — intervention group
Group type: EXPERIMENTAL
Intervention: high-MUFA diet plus physical activity program
Number of subjects: 45
Study 22723581 — intervention group
Group type: COMPARATOR
Intervention: high-carbohydrate/high-fiber/low-glycemic index diet
Number of subjects: 45
Study 22723581 — intervention group
Group type: COMPARATOR
Intervention: high-carbohydrate/high-fiber/low-glycemic index diet plus physical activity program
Number of subjects: 45
Study 20726734 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual coaching (by e‐mail, post, telephone or face‐to‐face) and a behaviour change website
Number of subjects: 208
Study 20726734 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change website
Number of subjects: 208
Study 20726734 — intervention group
Group type: EXPERIMENTAL
Intervention: Total duration of interventions by e‐mail
Number of subjects: 208
Study 20726734 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulting the physical activity feedback
Number of subjects: 208
Study 20726734 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfing depth
Number of subjects: 208
Study 18770021 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet delivered HIV risk reduction program
Number of subjects: 475
Study 12065968 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solution of powdered sweetener (Zero Cal)
Number of subjects: 12
Study 12065968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lactose solution
Number of subjects: 12
Study 12065968 — intervention group
Group type: COMPARATOR
Intervention: 1.5% sucrose solution
Number of subjects: 12
Study 12065968 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 12
Study 9726444 — intervention group
Group type: EXPERIMENTAL
Intervention: rG‐CSF 5 microg/kg for 5 consecutive days starting 7 days before chemotherapy with etoposide and cisplatin.
Number of subjects: 12
Study 9726444 — intervention group
Group type: COMPARATOR
Intervention: Historical group (CALGB 9132) with etoposide/cisplatin + rG‐CSF.
Number of subjects: 12
Study 9726444 — intervention group
Group type: EXPERIMENTAL
Intervention: Course 2 results after chemotherapy.
Number of subjects: 12
Study 9726444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both studies (present and historical) regarding ANC recovery.
Number of subjects: 12
Study 7974076 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose)
Number of subjects: 127
Study 7974076 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg 4 times daily for 7 days)
Number of subjects: 127
Study 2566827 — intervention group
Group type: EXPERIMENTAL
Intervention: haem arginate 3 mg/kg per 24 h for 4 days
Number of subjects: 12
Study 2566827 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 2566827 — intervention group
Group type: EXPERIMENTAL
Intervention: haem arginate
Number of subjects: 12
Study 31948466 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA + DHA (1.87 g/day of EPA + 1.0 g/day of DHA)
Number of subjects: 248
Study 31948466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 31127076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Treatment (CT)
Number of subjects: 87
Study 31127076 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Treatment (PT)
Number of subjects: 87
Study 31127076 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CTRL)
Number of subjects: 87
Study 29084499 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed algorithm based on thromboelastometry (TEM) results during bleeding episodes
Number of subjects: 16
Study 29084499 — intervention group
Group type: COMPARATOR
Intervention: Standard care including conventional laboratory coagulation tests
Number of subjects: 16
Study 26323938 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation
Number of subjects: 1325
Study 26323938 — intervention group
Group type: COMPARATOR
Intervention: Control (guideline-based medical treatment alone)
Number of subjects: 1325
Study 23850804 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized t(14;18)-positive follicular lymphoma
Number of subjects: 56
Study 23850804 — intervention group
Group type: EXPERIMENTAL
Intervention: Disseminated t(14;18)-positive follicular lymphoma
Number of subjects: 56
Study 23850804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal marginal zone lymphoma
Number of subjects: 56
Study 23850804 — intervention group
Group type: EXPERIMENTAL
Intervention: t(14;18)-negative follicular lymphoma
Number of subjects: 56
Study 20936314 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with Scutellaria baicalensis extract (SB)
Number of subjects: 40
Study 20936314 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (PLA)
Number of subjects: 40
Study 19809295 — intervention group
Group type: EXPERIMENTAL
Intervention: Full prediction model (0-22 points)
Number of subjects: 569
Study 19809295 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced prediction model (0-7 points)
Number of subjects: 569
Study 19809295 — intervention group
Group type: COMPARATOR
Intervention: Postoperative ARF occurrence
Number of subjects: 569
Study 16399265 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantity-comparison task
Number of subjects: 0
Study 16399265 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative-order judgment task
Number of subjects: 0
Study 15514193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) performed <2 weeks after nondisabling stroke
Number of subjects: 0
Study 15514193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 11238576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self rated health (poor to good)
Number of subjects: 21302
Study 11238576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self rated health (adjusted for medical history, cardiovascular risk factors, and education)
Number of subjects: 21302
Study 11238576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self rated health
Number of subjects: 21302
Study 9438480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg BD for 8 weeks
Number of subjects: 65
Study 9438480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 8 weeks
Number of subjects: 65
Study 9438480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 4 weeks followed by FPANS 200 microg BD for 4 weeks
Number of subjects: 65
Study 9438480 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for 8 weeks
Number of subjects: 65
Study 9438480 — intervention group
Group type: COMPARATOR
Intervention: Placebo OD for 8 weeks
Number of subjects: 65
Study 9438480 — intervention group
Group type: COMPARATOR
Intervention: Placebo OD for 4 weeks followed by placebo BD for 4 weeks
Number of subjects: 65
Study 9438480 — intervention group
Group type: COMPARATOR
Intervention: Placebo BD for 8 weeks
Number of subjects: 65
Study 8497284 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin (600 mg for 28 days)
Number of subjects: 71
Study 8497284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31783245 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 89
Study 31783245 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent participants
Number of subjects: 89
Study 31783245 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline adherence
Number of subjects: 89
Study 30891999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure ventilation in addition to conventional treatment
Number of subjects: 216
Study 30891999 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment including continuous oxygen inhalation, anti-infection, bronchodilation, phlegm resolving, nutrition support, analgesia, cardiac function maintenance, coronary dilatation, anticoagulation
Number of subjects: 216
Study 28430829 — intervention group
Group type: EXPERIMENTAL
Intervention: Displaying Medicare allowable fees for inpatient laboratory tests
Number of subjects: 98529
Study 25631295 — intervention group
Group type: EXPERIMENTAL
Intervention: Caterpillar cereal
Number of subjects: 175
Study 25631295 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 175
Study 23070062 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Well intervention (13-session peer-cofacilitated program)
Number of subjects: 63
Study 23070062 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Well intervention
Number of subjects: 63
Study 23070062 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study 21224868 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of 7.5 μg of vitamin D₃ for 12 months, increasing to 22.5 μg for the remaining 18 months through fortified dairy products and nutrition and lifestyle counselling sessions
Number of subjects: 66
Study 21224868 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 66
Study 19042080 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD4054 10 mg
Number of subjects: 312
Study 19042080 — intervention group
Group type: EXPERIMENTAL
Intervention: ZD4054 15 mg
Number of subjects: 312
Study 19042080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 16453185 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipradilol 0.25% twice daily for 3 months
Number of subjects: 50
Study 16453185 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 2% twice daily for 3 months
Number of subjects: 50
Study 16453185 — intervention group
Group type: EXPERIMENTAL
Intervention: Change to carteolol after nipradilol
Number of subjects: 50
Study 16453185 — intervention group
Group type: EXPERIMENTAL
Intervention: Change to nipradilol after carteolol
Number of subjects: 50
Study 16453185 — intervention group
Group type: COMPARATOR
Intervention: Comparison of additional IOP reduction
Number of subjects: 50
Study 15246467 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (APDs) + Antidepressants
Number of subjects: 0
Study 15246467 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics (APDs)
Number of subjects: 0
Study 11726261 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) 3 g/day for 3 weeks
Number of subjects: 10
Study 11726261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) for 3 weeks
Number of subjects: 10
Study 9230328 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (group 1)
Number of subjects: 110
Study 9230328 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (group 2)
Number of subjects: 110
Study 8390548 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent vaccine containing 10(4) TCID50 of B
Number of subjects: 50
Study 8390548 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent B vaccine of the same dose (10(4) TCID50)
Number of subjects: 50
Study 8390548 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent vaccine containing 10(6) TCID50 of B
Number of subjects: 50
Study 8390548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3102348 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (4.8 MIU aqueous procaine penicillin G plus 1 g oral probenecid)
Number of subjects: 540
Study 3102348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (1.5 g followed by 500 mg four times daily for four days)
Number of subjects: 540
Study 3102348 — intervention group
Group type: COMPARATOR
Intervention: Non-PPNG isolates susceptibility testing
Number of subjects: 540
Study 3102348 — intervention group
Group type: COMPARATOR
Intervention: Characterization of 226 non-PPNG isolates for plasmid content and auxotype
Number of subjects: 540
Study 28859868 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin solution (HAS) infusion
Number of subjects: 45
Study 27128197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan vicilin
Number of subjects: 25
Study 24253834 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 0.28
Number of subjects: 28
Study 24253834 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 0.50
Number of subjects: 28
Study 22484118 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day concomitant therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, tinidazole 500 mg twice daily)
Number of subjects: 90
Study 22484118 — intervention group
Group type: COMPARATOR
Intervention: 10-day sequential therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily for 5 days followed by esomeprazole 40 mg twice daily, levofloxacin 500 mg twice daily, tinidazole 500 mg twice daily for 5 more days)
Number of subjects: 90
Study 22484118 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day concomitant therapy
Number of subjects: 90
Study 22484118 — intervention group
Group type: COMPARATOR
Intervention: 10-day sequential therapy
Number of subjects: 90
Study 20025055 — intervention group
Group type: EXPERIMENTAL
Intervention: AAE581 (balicatib) at 0, 5, 10, 25, or 50 mg/D during 1 year
Number of subjects: 675
Study 20025055 — intervention group
Group type: COMPARATOR
Intervention: Control osteoporotic patients
Number of subjects: 675
Study 17721910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural body image therapy (BIT)
Number of subjects: 17
Study 17721910 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 17
Study 16446313 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II receptor blocker) for 4 months
Number of subjects: 60
Study 16446313 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 60
Study 16446313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15061232 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips
Number of subjects: 57
Study 15061232 — intervention group
Group type: COMPARATOR
Intervention: Tray-based 10% carbamide peroxide/dentifrice/mouth rinse combination system
Number of subjects: 57
Study 11326145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (3 g intravenous infusion)
Number of subjects: 31
Study 11326145 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (100 ml x 0.9% saline, placebo)
Number of subjects: 31
Study 11326145 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 controls, mean age 55 +/- 3 years)
Number of subjects: 31
Study 8840615 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (omeprazole 20 mg OD, bismuth subcitrate, amoxycillin)
Number of subjects: 62
Study 8840615 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (bismuth subcitrate 120 mg QID, amoxycillin 500 mg QID, metronidazole 400 mg TID for 2 weeks)
Number of subjects: 62
Study 1623756 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Treatment (OT)
Number of subjects: 51
Study 1623756 — intervention group
Group type: COMPARATOR
Intervention: Normal Treatment (NT)
Number of subjects: 51
Study 1623756 — intervention group
Group type: COMPARATOR
Intervention: Normal Treatment (NT) less than 4.5 L/min/m2
Number of subjects: 51
Study 1623756 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Treatment (OT) greater than 4.5 L/min/m2
Number of subjects: 51
Study 6595350 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal (IT) methotrexate plus 2,400 rad cranial irradiation (C)
Number of subjects: 104
Study 6595350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) methotrexate alone
Number of subjects: 104
Study 6595350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) methotrexate plus intravenous intermediate dose methotrexate
Number of subjects: 104
Study 30298556 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg oral capsule once daily before bedtime for 2 months)
Number of subjects: 74
Study 30298556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching capsules)
Number of subjects: 74
Study 29634604 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal nerve block
Number of subjects: 33
Study 29634604 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival injection
Number of subjects: 33
Study 27809791 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based health game targeting multiple cognitive domains
Number of subjects: 222
Study 27809791 — intervention group
Group type: COMPARATOR
Intervention: waiting list (control group)
Number of subjects: 222
Study 24962875 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (1 billion CFU of Lactobacillus casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, B. infantis, L. bulgaricus and fructooligosacharide)
Number of subjects: 50
Study 24962875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24962875 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 50
Study 22823334 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PAN‐1)
Number of subjects: 72
Study 22823334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SA (CSA‐1)
Number of subjects: 72
Study 22823334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Unicem (RXU‐1)
Number of subjects: 72
Study 22823334 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PAN‐2)
Number of subjects: 72
Study 22823334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SA (CSA‐2)
Number of subjects: 72
Study 22823334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Unicem (RXU‐2)
Number of subjects: 72
Study 21186921 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver acetate solution
Number of subjects: 20
Study 21186921 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (placebo)
Number of subjects: 20
Study 17420902 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo (400 U/kg, subcutaneously twice a week)
Number of subjects: 34
Study 17420902 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study 17420902 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo (800 U/kg/week)
Number of subjects: 34
Study 16787959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dodecanedioic acid (C-12)
Number of subjects: 0
Study 16787959 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 0
Study 16787959 — intervention group
Group type: COMPARATOR
Intervention: Water load
Number of subjects: 0
Study 12909068 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angiography without tirofiban pre‐treatment
Number of subjects: 220
Study 12909068 — intervention group
Group type: COMPARATOR
Intervention: Delayed angiography after 24‐48h pre‐treatment with tirofiban
Number of subjects: 220
Study 10470637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand bent at 20 degrees
Number of subjects: 270
Study 10470637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand bent at 80 degrees
Number of subjects: 270